BC Extra | Jul 19, 2019
Financial News

July 19 Financial Quick Takes: Amarin raises cash ahead of Vascepa PDUFA date, plus Atara, Sunstone and Forendo

Ahead of Vascepa push, Amarin adds $400M to coffers  With the Sept. 28 PDUFA date looming for a potential expansion of the label for Vascepa icosapent to include reduced cardiovascular risk, Amarin Corp. plc (NASDAQ:AMRN)...
BC Innovations | May 3, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer In vitro and cell-based studies identified a dual STS / HSD17B1 inhibitor that could help treat breast cancer. Chemical synthesis and in vitro testing of aryl sulfamate analogs identified a compound that...
BC Extra | Oct 23, 2014
Financial News

Forendo closes EUR 12M series A

Forendo Pharma Oy (Turku, Finland) closed a EUR 12 million ($15.3 million) series A round led by new investors Novartis Venture Fund and MS Ventures. Existing investors including Karolinska Development AB ; Novo Seeds; and...
BC Innovations | Dec 19, 2013
Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical...
BC Week In Review | Nov 25, 2013
Company News

AmorChem, CHU de Quebec, Universite Laval deal

VC fund AmorChem partnered with the university and CHU to develop compounds to treat endometriosis and estrogen-dependent cancers. The collaborators will focus on the preclinical development of hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1) inhibitors discovered by...
BioCentury | Oct 14, 2013
Emerging Company Profile

Forendo: Fixing endometriosis

Forendo Pharma Oy is developing inhibitors of hydroxysteroid 17-beta dehydrogenase 1 to treat endometriosis without depleting circulating estrogen, thus avoiding side effects of available therapies. In endometriosis, tissue similar to endometrium in the uterus grows...
BC Innovations | Feb 16, 2012
Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Breast cancer; endometriosis Hydroxysteroid 17-b dehydrogenase 1 (HSD17B1) In vitro and cell culture studies identified HSD17B1 inhibitors that could treat estrogen-dependent...
BC Innovations | Oct 22, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Hydroxysteroid 17-b dehydrogenase 1 (HSD17B1) Studies in cell cultures suggest that thienopyrimidinone inhibitors of HSD17B1 could help treat hormone-dependent breast cancer. Inhibiting HSD17B1...
Items per page:
1 - 8 of 8